“Neurotech” gets used as a catchall for everything from meditation headbands to Elon Musk’s brain implants, and that’s part of the problem. Lump them together and you lose the distinction that actually matters here: what stage each technology is actually at. A lab demo, an early clinical trial, and a device you can order online are not the same thing, even when headlines cover them the same way.
This list sorts through that noise. It ranks the neurotech developments most likely to affect an ordinary person’s life by 2035, not by hype, but by where each one sits today: cleared and shipping, mid-trial and years from a decision, or still confined to a government contractor’s lab. Medical, consumer, and military neurotech are moving on very different timelines, and conflating them is how a research paper starts sounding like a product on a shelf. Here’s what’s actually happening, company by company, trial by trial. Worth asking yourself as you read: which of these would you actually want on or in your body?
A neck patch is already giving paralyzed patients their hands back
Start with the one that’s not really a “brain” interface at all, and is already commercially available. Onward Medical’s ARC-EX is a non-invasive spinal cord stimulator, electrodes on the back of the neck, no surgery, that the FDA cleared in December 2024 and expanded to home use in November 2025. It doesn’t decode brain signals. It stimulates dormant circuitry in the spinal cord itself, reactivating nerve fibers that survived an injury but went quiet.
The results are the kind of specific this audience wants:
The pivotal Up-LIFT trial enrolled 65 people with chronic tetraplegia at 14 centers across the US, Europe, and Canada
90% of participants improved upper-limb strength or function
87% reported a better quality of life, with no serious adverse events
Results were published in Nature Medicine, not a press release
Onward’s CEO, Dave Marver, has been explicit that ARC-EX is not a cure, and that it works best paired with intensive rehab, not instead of it. The company is also developing an implantable version (ARC-IM) and a BCI-powered platform, but those remain investigational. If you or someone you know lives with a spinal cord injury, Onward’s own therapy page lists which rehab centers currently carry the device, and it’s worth a five-minute look.
Brain implants are moving from demo to device, just not all at the same speed
This is the category everyone pictures when they hear “brain-computer interface,” and it’s also the one most prone to getting flattened into a single narrative. It isn’t one. Three companies are running genuinely different plays.
Neuralink has implanted its N1 device, up to 3,072 electrodes on 64 threads, in roughly two dozen patients globally as of mid-2026, most through its PRIME study for people with paralysis from spinal cord injury or ALS. A parallel VOICE trial, which holds FDA Breakthrough Device Designation, is teaching the implant to reconstruct a patient’s pre-illness voice from imagined speech; one participant’s restored voice was built from old recordings made before ALS took his speech. That’s a striking result. It is also, still, a clinical trial, not a shipping product.
Synchron takes the opposite surgical approach. Its Stentrode implant is delivered through the jugular vein via catheter, like a cardiac stent, and sits inside a blood vessel next to the motor cortex rather than penetrating brain tissue. No craniotomy required. The tradeoff is signal resolution, reading through a vessel wall is noisier than reading off exposed cortex. Synchron’s COMMAND feasibility study met its safety endpoints in six patients, and the company raised $200 million to fund a 2026 pivotal trial aimed at the first-ever PMA approval for an implanted BCI. CEO Dr. Tom Oxley has said plainly that whichever company runs the first successful pivotal trial, not the flashiest demo, will define where the field actually stands.
Precision Neuroscience sits between the two. Its Layer 7 Cortical Interface, a film thinner than a human hair carrying 1,024 electrodes, rests on the brain’s surface without penetrating it and received FDA 510(k) clearance in 2025, but only for temporary use (up to 30 days) in intraoperative brain mapping. It is not yet a full implantable BCI system; that product is still in development. Founder Benjamin Rapoport, who also co-founded Neuralink, has framed the clearance as a foundation rather than a finish line.
For deeper context on how fast this category is professionalizing, NeurotechMag’s own read on the tipping point is worth a look, and it lines up with what the trial data above actually shows.
Your wrist, not your skull, is where consumer neurotech actually landed first
Here’s where the terminology gets slippery, and where this publication insists on precision. Meta’s Neural Band, bundled with the $799 Ray-Ban Display glasses since September 2025, is often described in casual coverage as “mind-reading.” It isn’t. The wristband uses electromyography (EMG), reading electrical signals traveling from the spinal cord to hand muscles, not signals from the brain itself. It detects motor intent milliseconds before a finger actually twitches, letting you scroll or click with a barely visible gesture.
That distinction matters clinically too. At CES 2026, Meta announced a research partnership with the University of Utah exploring whether the same wristband could let people with ALS or muscular dystrophy control smart-home devices, lights, thermostats, locks, using residual muscle signals too subtle for normal detection. That’s a real, near-term application. A few things worth knowing about where this stands:
Already commercially available in the US, expanding to Canada, France, Italy, and the UK in early 2026
No implant, no surgery, classified by Meta as non-invasive peripheral sensing
Cannot detect internal thought or “cognitive reflections,” only intended muscle activation
A parallel research track is testing the same hardware for accessibility, not just AR control
Consumer BCI marketing loves to blur this line because “reads your mind” sells better than “detects motor neuron output at the wrist.” One is accurate. One isn’t.
Wellness EEG headbands are quietly building a real market, medical claims aside
Unlike the wristband above, devices like Muse, Emotiv’s EPOC X, and Neurable’s MW75 Neuro headphones do read actual brain electrical activity via EEG sensors against the scalp. What they can’t do is decode specific thoughts. They detect broad patterns, alpha waves during relaxation, beta activity during focus, and translate those patterns into feedback: a chime when your meditation session deepens, a nudge when your attention drifts during work.
None of these are medical devices, and reputable companies in the space are careful to say so. What’s changed recently:
NextSense launched in-ear EEG “Smartbuds” in February 2026, moving sensors off a headband and into something that looks like earbuds
Interaxon’s Muse S Athena added fNIRS (a blood-oxygenation signal) alongside EEG for more reliable sleep and relaxation tracking
The wearable EEG category is now projected to grow 10 to 17% annually, driven mostly by sleep, focus, and meditation use cases rather than anything medical
OpenBCI’s Galea and Ultracortex remain the go-to open-source platforms for developers who want to build on raw signal data themselves
If you’re curious which of these are actually worth buying today rather than waiting on, NeurotechMag’s rundown of devices you can purchase right now is a useful starting point before you spend money on hardware that promises more than EEG can currently deliver.
The most consequential program in this space might be the one that stopped talking
Save the murkiest one for last. DARPA’s Next-Generation Nonsurgical Neurotechnology program, N3 for short, funded six research groups in 2019, Battelle, Carnegie Mellon, Johns Hopkins’ Applied Physics Laboratory, PARC, Rice University, and Teledyne, to build bidirectional, non-surgical neural interfaces for able-bodied soldiers. The stated goals were straightforward on paper: hands-free control of drone swarms, direct interaction with cyber-defense systems, faster multitasking under combat stress.
The program had a four-year timeline and, by DARPA’s own account, reached human testing before its public page was marked complete and no longer maintained. When asked for details, DARPA’s response was that it “does not operationalize technologies” and that research teams would share more in 2026. That’s a notably thin answer for a publicly funded program that reached human subjects.
A few things are worth separating clearly here, because military coverage of this topic tends to run toward speculation fast:
N3’s stated goal was non-invasive interfaces, unlike the surgical implants covered above
The program is confirmed to have reached Phase III human testing, per DARPA’s own program history
What specifically was tested, and with what results, has not been made public
There is no confirmed evidence these interfaces have been operationally deployed
That gap between “reached human trials” and “we won’t say what happened” is the story. If that kind of opacity bothers you as much as it bothers us, it’s worth keeping an eye on which of DARPA’s research partners eventually spin their work into published papers or commercial ventures, since that’s usually the first real signal of where classified neurotech research actually lands.
Line those five up and the pattern is clear: the closer a technology gets to your body’s own signal pathways rather than your skull, the faster it reaches the market. ARC-EX and the Neural Band are already real. The brain implants are close, but on genuinely different clocks depending on surgical approach. The military program may already have answers nobody outside a classified briefing has seen. Which of these five would you actually let onto your own body first, and which one worries you the most?